Login
Enter your Progress In Mind Portugal username.
Enter the password that accompanies your username.

Request new password

Home

Progress in Mind Portugal

  • Topics
    • Depression
    • Migraine
    • Schizophrenia
  • Congress highlights
    • EAN 2022
    • AAN 2022
    • AHS 2022
    • AAN 2021
    • AHS 2021
    • IHC 2021
    • SIRS 2019
    • EPA 2019
    • EPA 2018
    • APA 2018
    • ECNP 2017
  • About
  • Podcasts
  • Newsletter signup

Search

Main navigation

  • Home
  • Lundbeck Therapeutic Area Australia
  • Progress in Mind Korea Focus Area
  • Progress in Mind Spain Focus Area
  • 전문가 칼럼
  • 찾아보기

Tools

  • 찾아보기
  • User Profile

User account menu

  • Log in
  • Reset your password
Powered by Drupal

The information on this site is exclusively intented for health care professionals.

Accept Decline
Schizophrenia 12 Aug, 2019

Video #6: Which patients are best suited for long-acting injectable antipsychotics?

 Professor John Kane discusses the often-asked question, who is the ideal candidate for long-acting antipsychotic treatment?

Sign up for Progress in Mind Portugal newsletter

Sign up for our newsletter and stay updated on new content and resources.

Related

Migraine
Congress highlights

Do anti-CGRP monoclonal antibodies alter the expected course of migraine?

Bipolar
Satellite symposium

Maintaining functioning in bipolar disorder: Treat early and prevent relapses

Depression
Congress highlights

One disease or many – the complexity of major depressive disorder

Social Networks

Progress in Mind Portugal HCP Access verification required

To gain access, please provide details to verify you are a healthcare professional.

If you are not located in Portugal click here.

Continue to verification page Login with email

Brought to you by

 Lundbeck

© 2021

PROGRESS IN MIND PORTUGAL

Cookies

Condições de Utilização

subscribe newsletter

Sign up for newsletter

Register as a health care professional

Login as a registered health care professional

Please enter your email to continue

By submitting this form you agree that your email is sent to a third party for validation.

Read the full terms and conditions here.